Fusidic Acid Topical Composition for Epidermolysis Bullosa Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epidermolysis bullosa (EB) lack effectiveness in managing non-healing wounds, chronic wounds, and lesional skin, with no clear consensus on the best treatment strategies and no cure available.
Innovation Solution
A topical composition comprising fusidic acid and pharmaceutically acceptable excipients is applied to the skin of individuals with EB, aiming to reduce scar formation, prevent infection, and promote wound healing by altering the skin microbiome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for epidermolysis bullosa, then disease management is provided, but wound healing effectiveness is insufficient and scar formation occurs
Solution Approach 1:
The patent changes the chemical parameter of the treatment by introducing fusidic acid, a specific antibiotic agent, to alter the bacterial environment on the skin. This parameter change targets the root cause of non-healing wounds by addressing bacterial dysbiosis, thereby improving wound healing effectiveness where previous treatments failed.
Solution Approach 2:
The treatment approach combines fusidic acid with topical application methodology to create a composite therapeutic intervention. This composite solution addresses multiple aspects of wound care simultaneously - antimicrobial action, inflammation control, and wound bed preparation - resolving the lack of consensus by providing an integrated treatment protocol.
2Productivity
If topical fusidic acid composition is applied, then wound healing rate improves and scar formation reduces, but skin infection prevention challenge remains
Solution Approach 1:
The patent converts the harmful presence of dysbiotic bacteria into a beneficial outcome by using fusidic acid to selectively eliminate pathogenic species. This transforms the infected wound environment into a healed, balanced skin microbiome, simultaneously addressing wound healing and infection prevention through the same mechanism.
Solution Approach 2:
Fusidic acid acts as an intermediary agent between the dysbiotic skin environment and the desired healed state. It mediates the interaction by selectively targeting harmful bacteria while preserving beneficial microbiota, thereby improving wound healing rates without compromising infection prevention.
3Reliability
If topical composition is applied to alter skin microbiome, then bacterial diversity changes and wound healing improves, but treatment complexity increases
Solution Approach 1:
The patent extracts and targets only the specific pathological element - dysbiotic bacteria - rather than attempting to modify the entire skin microbiome comprehensively. By focusing fusidic acid action on specific pathogenic species, the treatment achieves reliable wound healing outcomes while maintaining relative simplicity in composition and application protocol.
Data Source
AI summary
Provided herein are compositions for topical application to a subject, for treating epidermolysis bullosa (EB). Also disclosed are methods for treating skin in a person suffering from EB. The methods comprise providing a composition comprising fusidic acid and one or more pharmaceutically acceptable excipients; and topically applying, or instructing to topically apply, the composition to skin of a person suffering from EB. In some embodiments, the composition is topically administered to treat a non-healing wound, chronic wound or lesional skin in a patient suffering from EB, to reduce the likelihood of skin infections, to reduce the likelihood of scar formation, to prevent or reduce the risk of a skin blister from becoming infected, to treat intact blisters on skin, to treat skin dysbiosis, to alter bacterial diversity of the skin microbiome, or to increase the quality of life in a subject suffering from EB.